Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh .
作者信息
Zheng Jieling, Zhang Bin
机构信息
Radiology, Jinan University First Affiliated Hospital, Guangzhou, Guangdong, China.
Radiology, Jinan University First Affiliated Hospital, Guangzhou, Guangdong, China
出版信息
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004965.
Abstract
摘要
相似文献
1
Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh .关于Jazieh的《新型影像生物标志物预测接受放化疗和度伐鲁单抗治疗的III期不可切除非小细胞肺癌的预后》的通信
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004965.
2
Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng .对郑关于《新型成像生物标志物预测接受放化疗和度伐鲁单抗治疗的 III 期不可切除非小细胞肺癌的预后》的通信的回复 。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005086.
3
Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.多柔比星联合顺铂同期放化疗治疗肺多形性癌的长期疗效：1 例报告。
Thorac Cancer. 2020 Apr;11(4):1090-1093. doi: 10.1111/1759-7714.13331. Epub 2020 Feb 11.
4
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.在不可切除的 III 期非小细胞肺癌的真实世界患者中，放化疗后使用度伐利尤单抗进行巩固治疗。
Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 Apr 13.
5
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.接受放化疗和度伐利尤单抗治疗的 III 期非小细胞肺癌的临床结局、局部区域控制和转移导向治疗的作用。
Radiother Oncol. 2020 Aug;149:205-211. doi: 10.1016/j.radonc.2020.04.047. Epub 2020 Apr 30.
6
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.度伐利尤单抗联合放疗用于不可切除的 III 期 NSCLC 患者，这些患者由于不适合化疗而无法接受化疗。
Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15.
7
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.不可切除 III 期非小细胞肺癌中使用及妨碍使用度伐利尤单抗巩固治疗的因素。
Radiother Oncol. 2020 Mar;144:101-104. doi: 10.1016/j.radonc.2019.11.015. Epub 2019 Nov 28.
8
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.durvalumab 联合放化疗治疗不可切除 III 期非小细胞肺癌（PACIFIC）患者的报告结果：一项随机、对照、III 期临床研究。
Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.
9
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.检测不可切除的 III 期非小细胞肺癌患者接受放化疗时使用 22C3 抗体的程序性细胞死亡配体 1。
Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7.
10
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
本文引用的文献
1
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.新型影像学生物标志物预测放化疗联合度伐利尤单抗治疗不可切除 III 期非小细胞肺癌的结局。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003778.
2
Predicting cancer outcomes with radiomics and artificial intelligence in radiology.利用放射组学和人工智能技术预测癌症预后。
Nat Rev Clin Oncol. 2022 Feb;19(2):132-146. doi: 10.1038/s41571-021-00560-7. Epub 2021 Oct 18.
3
The Biological Meaning of Radiomic Features.放射组特征的生物学意义。
Radiology. 2021 Mar;298(3):505-516. doi: 10.1148/radiol.2021202553. Epub 2021 Jan 5.
4
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.克服 PD-1 阻断的基于遗传的耐药机制。
Cancer Discov. 2020 Aug;10(8):1140-1157. doi: 10.1158/2159-8290.CD-19-1409. Epub 2020 May 28.
5
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
Zotero 插件